Neuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling
Journal of Clinical Investigation · 15.11.2024 · 134 (22)
DOI: 10.1172/jci181368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.10.2024. Verfasst von Ayush Kumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell and Cancer Biology. Hauptthemen laut MEDLINE: Neuropilin-2, Nitric Oxide, Oxidative Stress, Signal Transduction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH Office of the Director.
Abstract (Originalsprache)
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular, Cell and Cancer Biology.
- Department of Radiation Oncology.
- Department of Pathology, and.
- Department of Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- NIH Office of the Director
Zitieren
APA
Kumar, A., Goel, H. L., Silva, C. A., Wang, T., Geng, Y., Wang, M., Goel, S., Hu, K., Li, R., Zhu, L. J., Clark, J. L., Ferreira, L. M., Brehm, M. A., FitzGerald, T. J., & Mercurio, A. M. (2024). Neuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling. Journal of Clinical Investigation, 134(22). https://doi.org/10.1172/jci181368
Vancouver
Kumar A, Goel HL, Silva CA, Wang T, Geng Y, Wang M, et al. Neuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling. Journal of Clinical Investigation. 2024;134(22). doi:10.1172/jci181368
BibTeX
@article{Kumar2024,
author = {Kumar, Ayush and Goel, Hira Lal and Silva, Christi A and Wang, Tao and Geng, Yansong and Wang, Mengdie and Goel, Shivam and Hu, Kai and Li, Rui and Zhu, Lihua J and Clark, Jennifer L and Ferreira, Lindsay M and Brehm, Michael A and FitzGerald, Thomas J and Mercurio, Arthur M},
title = {Neuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {22},
doi = {10.1172/jci181368}
}
EUVIMED